Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00951028 · ClinicalTrials.gov registry record · NA
Therapy Targeting Depression and HIV Treatment Adherence (The TRIAD Study)
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 240
- Enrollment target
NCT00951028: Completed NA study, sponsored by Massachusetts General Hospital.
NCT00951028 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 240 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00951028, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 240 participants
- Enrollment target
Study Summary
This study will test a therapy for both helping people adhere to their HIV medication regimens and treating them for depression.
Interventions
- BEHAVIORAL Cognitive behavioral therapy (CBT) for adherence and depression (CBT-AD)
- BEHAVIORAL Life-steps adherence treatment
- BEHAVIORAL Information and supportive psychotherapy (ISP) for adherence and depression (ISP-AD)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2008-09 |
| Est. Completion | 2013-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00951028
The ClinicalTrials.gov registry entry for NCT00951028 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cognitive behavioral therapy (CBT) for adherence and depression (CBT-AD) is the first listed.
NCT00951028 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00951028 about?
NCT00951028 is a clinical study titled "Therapy Targeting Depression and HIV Treatment Adherence (The TRIAD Study)". This study will test a therapy for both helping people adhere to their HIV medication regimens and treating them for depression.
What is the current status of trial NCT00951028?
This trial is currently completed. It is a NA study. The enrollment target is 240 participants. The study started on 2008-09. Estimated completion is 2013-04.
What interventions are being tested in trial NCT00951028?
The interventions under investigation include: Cognitive behavioral therapy (CBT) for adherence and depression (CBT-AD) (BEHAVIORAL), Life-steps adherence treatment (BEHAVIORAL), Information and supportive psychotherapy (ISP) for adherence and depression (ISP-AD) (BEHAVIORAL).
Who is sponsoring clinical trial NCT00951028?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.